ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 177 filers reported holding ENANTA PHARMACEUTICALS INC in Q3 2019. The put-call ratio across all filers is 1.35 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,211 | -44.2% | 735,103 | +6.9% | 3.02% | -35.2% |
| Q2 2023 | $14,715 | -39.7% | 687,613 | +14.0% | 4.66% | -37.1% |
| Q1 2023 | $24,397 | -11.8% | 603,301 | +1.4% | 7.41% | -13.3% |
| Q4 2022 | $27,671 | -99.9% | 594,818 | +0.9% | 8.55% | -12.2% |
| Q3 2022 | $30,570,000 | +3.5% | 589,360 | -5.7% | 9.73% | -0.3% |
| Q2 2022 | $29,533,000 | -24.4% | 624,768 | +13.8% | 9.76% | -27.5% |
| Q1 2022 | $39,066,000 | -7.4% | 548,828 | -2.7% | 13.46% | -8.0% |
| Q4 2021 | $42,184,000 | -20.7% | 564,102 | -39.8% | 14.63% | -12.4% |
| Q3 2021 | $53,218,000 | +28.7% | 936,777 | -0.3% | 16.69% | +18.9% |
| Q2 2021 | $41,354,000 | -2.8% | 939,650 | +8.9% | 14.04% | -4.7% |
| Q1 2021 | $42,556,000 | +17.7% | 862,848 | +0.5% | 14.73% | +39.5% |
| Q4 2020 | $36,156,000 | -4.3% | 858,811 | +4.1% | 10.56% | -12.2% |
| Q3 2020 | $37,784,000 | -1.4% | 825,329 | +8.2% | 12.03% | +15.4% |
| Q2 2020 | $38,315,000 | +6.4% | 763,103 | +9.0% | 10.42% | -10.0% |
| Q1 2020 | $36,017,000 | +19.1% | 700,318 | +43.1% | 11.58% | +12.3% |
| Q4 2019 | $30,234,000 | +0.9% | 489,385 | -1.9% | 10.32% | -10.3% |
| Q3 2019 | $29,972,000 | -25.9% | 498,874 | +4.0% | 11.51% | -12.4% |
| Q2 2019 | $40,467,000 | -11.0% | 479,576 | +0.7% | 13.13% | +6.9% |
| Q1 2019 | $45,472,000 | +20.0% | 476,042 | -11.0% | 12.29% | -3.9% |
| Q4 2018 | $37,882,000 | -13.3% | 534,825 | +4.6% | 12.79% | +13.9% |
| Q3 2018 | $43,686,000 | -27.4% | 511,186 | -1.5% | 11.23% | -26.9% |
| Q2 2018 | $60,156,000 | +0.5% | 519,035 | -29.8% | 15.36% | +5.8% |
| Q1 2018 | $59,852,000 | +17.7% | 739,738 | -14.7% | 14.52% | -8.4% |
| Q4 2017 | $50,862,000 | +7.2% | 866,770 | -14.5% | 15.85% | +7.2% |
| Q3 2017 | $47,448,000 | +19.3% | 1,013,847 | -8.2% | 14.79% | +22.5% |
| Q2 2017 | $39,758,000 | +17.5% | 1,104,992 | +0.6% | 12.07% | +10.6% |
| Q1 2017 | $33,835,000 | -4.3% | 1,098,524 | +4.1% | 10.91% | -14.0% |
| Q4 2016 | $35,367,000 | +32.9% | 1,055,719 | +5.6% | 12.68% | +31.9% |
| Q3 2016 | $26,603,000 | +33.0% | 999,741 | +10.2% | 9.61% | +33.4% |
| Q2 2016 | $19,998,000 | -22.8% | 906,930 | +2.8% | 7.20% | -22.5% |
| Q1 2016 | $25,920,000 | -10.6% | 882,529 | +0.5% | 9.30% | +0.5% |
| Q4 2015 | $29,006,000 | +9.9% | 878,446 | +20.3% | 9.26% | -3.1% |
| Q3 2015 | $26,393,000 | -17.0% | 730,308 | +3.3% | 9.55% | -20.4% |
| Q2 2015 | $31,804,000 | +145.0% | 706,908 | +66.7% | 12.00% | +102.9% |
| Q1 2015 | $12,983,000 | – | 424,016 | – | 5.91% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 511,186 | $43,686,000 | 11.23% |
| GREAT POINT PARTNERS LLC | 210,400 | $17,981,000 | 2.80% |
| ARMISTICE CAPITAL, LLC | 456,000 | $38,970,000 | 2.34% |
| Matarin Capital Management, LLC | 210,208 | $17,964,376,000 | 1.16% |
| Sapphire Star Partners LP | 8,168 | $698,000 | 0.70% |
| Granahan Investment Management | 103,320 | $8,830,000 | 0.48% |
| FARALLON CAPITAL MANAGEMENT LLC | 867,500 | $74,137,000 | 0.44% |
| 361 CAPITAL LLC | 19,040 | $1,627,000 | 0.35% |
| ALGERT GLOBAL LLC | 17,922 | $1,532,000 | 0.33% |
| AlphaMark Advisors, LLC | 9,310 | $796,000 | 0.32% |